UPDATE 2-US advisers reject new use for J&J/Bayer's Xarelto - Reuters

SILVER SPRING, Md., May 23 (Reuters) - U.S. advisers recommended against expanding the use of Johnson & Johnson's blood thinner Xarelto as a way to reduce the risk of new heart attacks and strokes in people with heart problems. A panel of ...

UPDATE 3-FDA staff sends mixed message on J&J drug Xarelto - Reuters

WASHINGTON, May 21 (Reuters) - U.S. drug reviewers had mixed opinions about whether Johnson & Johnson blood thinner Xarelto reduced the risk of new heart attacks and strokes in people with heart problems, setting the stage for heated debate by ...

J&J’s Blood Thinner Rejected by Panel for Expanded Use - Businessweek

Johnson & Johnson (JNJ) (JNJ) and Bayer AG (BAYN)’s blood-thinner Xarelto failed to win the backing of a U.S. advisory panel for broader use to prevent heart attacks and strokes in patients with a common heart ailment. Advisers to the Food and ...

Bayer’s Xarelto Backed in Final Stroke Guidance From U.K.’s NICE - Businessweek

The U.K.’s National Institute for Health and Clinical Excellence published final guidance recommending Bayer AG (BAYN)’s Xarelto blood-thinner as a cost- effective way to prevent strokes in people with an irregular heartbeat known as atrial ...

UK's NICE Gives Final OK for Bayer's Xarelto To Prevent Strokes - NASDAQ

FRANKFURT -(Dow Jones)- The U.K.'s healthcare cost-effectiveness body Wednesday issued its final recommendation for Bayer AG's (BAYN.XE) anti-clotting pill Xarelto as an option for the prevention of stroke and systemic embolism in people with ...

FDA review backs Xarelto for big new use in ACS patients - FiercePharma

Xarelto could be one step closer to justifying the aggressive sales projections tossed out by Bayer CEO Marijn Dekkers. The anticoagulant won a thumbs-up from FDA's clinical reviewer, ahead of Wednesday's advisory panel meeting, where FDA ...

Johnson & Johnson Setback Is Positive for Pfizer, Bristol-Myers - Minyanville

The shares are down 7% this year. Wall Street analysts expect Eliquis will be approved and now that J&J has a negative vote from FDA advisers, the odds are that Xarelto’s use won’t be expanded next month. (Eliquis didn’t face an FDA panel.)

FDA review: J&J's Xarelto reduces heart attack-causing clots - MyCentralJersey.com

WASHINGTON — The Food and Drug Administration said Monday that a blood thinner from New Brunswick–based Johnson & Johnson appears to reduce life-threatening blood clots in high-risk patients, although it also increases the risk of internal ...

FDA Panel Votes Against New Use for Blood Thinner Xarelto - Newsday

An advisory panel to the U.S. Food and Drug Administration on Wednesday voted against a new use of a new blood thinner, Xarelto, to cut the risk of potentially lethal clots in people with acute coronary syndrome. The panel of experts voted 6-to ...

FDA panel votes against new use for J&J's Xarelto - Yahoo Finance

WASHINGTON (AP) -- A majority of Food and Drug Administration panelists voted against a new use for Johnson & Johnson's blood thinner Xarelto to reduce life-threatening blood clots. The FDA's panel of experts voted 6-4 Wednesday against the new ...